LINKINVAX
French tech company | Builders Republic
About
Clinical-stage biotech that develops vaccines and immunotherapies using a dendritic-cell-targeting platform — directing antigens to immune cells to trigger stronger responses against infectious diseases and cancer, licensed from the Vaccine Research Institute (Inserm). Spin-off in oncology and infectious indications.
Key facts
- Status
- Morte
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2020
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 3.0 M€ raised since 2020
Funding rounds
- Seed — 2023
Investors
- In-q-tel
Notes
Opère sous EnnoDC (nom commercial) depuis 2024 — pivot stratégique de la plateforme de ciblage des cellules dendritiques vers l'immuno-oncologie ; entité juridique LinKinVax Europe SAS conservée